Bannerbild German Brest Group

GBG Research at ESMO

15.10.2018

Data of several GBG trials and translational research projects will be presented at the upcoming ESMO 2018 Congress, which will take place from 19 to 23 October in Munich, Germany.

Clinical trials

GeparSepto (GBG 69, NCT 01583426): results of follow-up

#188PD: Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)

  • Session: Poster Discussion session - Breast cancer, early stage; 20.10.2018, 15:00 - 16:15; Hall A1 - Room 15 (poster discussion)
  • First author: M. Untch; HELIOS Klinikum Berlin-Buch, Berlin; Germany


MALE (GBG 54, NCT01638247): final analysis

#273PD: Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients

  • Session: Poster Discussion session - Breast cancer, metastatic; 21.10.2018; 09:15 - 10:30; ICM - Room 1(poster discussion)
  • First author: M Reinisch; Kliniken Essen-Mitte, Essen, Germany


AMICA (GBG 97, NCT03555877): trial in progress

#364TiP: Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: a phase II trial (AMICA) GBG 97

  • Session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care; 22.10.2018; 12:45 - 13:45; Hall A3 - Poster Area Networking Hub (TIP poster)
  • First author: T. Decker; Hämatologie, Onkologie, Ravensburg, Germany


PATINA (GBG 94, AFT-38, NCT02947685): trial in progress

#369TiP: PATINA: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy (ET) vs. Anti-HER2 Therapy + ET after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer (MBC)

  • Session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care; 22.10.2018; 12:45 - 13:45; Hall A3 - Poster Area Networking Hub (TIP poster)
  • First author: S. Loibl, German Breast Group, Neu-Isenburg; Germany


Translational research

Results using samples obtained from patients with early breast cancer enrolled in PREPARE and TECHNO trials

#227P: Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) Subtypes

  • Session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care; 22.10.2018; 12:45 - 13:45; Hall A3 - Poster Area Networking Hub (poster)
  • First author: P.A. Fasching; Department of Gyn/Ob, Universitätsklinik Erlangen, Germany


#168P: Validation of the MammaTyper® pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC)

  • Session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research; 20.10.2018; 12:30 - 13:30; Hall A3 - Poster Area Networking Hub (poster)
  •  First author: P.A. Fasching; Department of Gyn/Ob, Universitätsklinik Erlangen, Germany


Results using samples obtained from patients with TNBC enrolled in GeparOcto trial (GBG 84, NCT02125344)

#243P: Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study

  • Session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care; 22.10.2018; 12:45 - 13:45; Hall A3 - Poster Area Networking Hub (poster)
  • First author: E. Pohl-Rescigno; Center for Familial Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany


More Information about ESMO 2018 is available on this website.

News

  • 29.11.2018 GBG Research at SABCS

    Data of several GBG trials and translational research projects will be presented at the upcoming SABCS 2018 Congress, which will take place from 4-8 December in San Antonio, Texas, USA.

    Mehr ...
  • 15.11.2018 Save the Date: AGO-Mamma 2019

    Save the Date: AGO-Mamma 2019

    Das State-of-the-Art-Meeting 2019 der AGO Organkomission Mamma wird am 16. März 2019 in Frankfurt stattfinden.

    Mehr ...
  • 05.11.2018 October 2018: Long-term survival analysis of GeparSixto trial

    The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.

    Mehr ...
  • 11.10.2018 BIG newsletter no 9 is out

    We’re delighted to announce that the BIG newsletter BIG Research in Focus, Issue 9 is out and has been published on BIG’s website.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd